Adjuvant chemo-immunotherapy after curative resection of stage II and IIIA primary lung cancer

Lung Cancer

Volumn 14, Issue 2-3, 1996, Pages 301-314

  Kimura, Hideki ^a   Yamaguchi, Yutaka ^b  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Adjuvant therapy; IL 2; Immunotherapy; LAK cells; Lung cancer; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; INTERLEUKIN 2; MITOMYCIN C; VINDESINE;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; FEMALE; HUMAN; LUNG CANCER; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0029973720     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-5002(96)00555-7     Document Type: Article

References (23)

1. Green MR. Dose adjuvant chemotherapy decreases distant metastasis formation in patients with non-small cell lung cancer? Lung Cancer 1994: 10 Suppl: S187-S194.
2. Payne DG. Is preoperative or postoperative radiation therapy indicated in non-small cell cancer of the lung? Lung Cancer 1994; 10 Suppl: S205-S212.
3. Kimura H, Yamaguchi Y. Controlled randomized study on adoptive immunotherapy for resected primary lung cancer patients (in Japanese). Jpn J Chest Dis 1995; 54: 451-457.
4. Kimura H, Yamaguchi Y. Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer. Lung Cancer 1995; 13: 31-44.
5. Kimura H, Yamaguchi Y, Fujisawa T. Cytotoxicity of autologous and allogenic lymphocytes against cultured human lung cancer cells: optimal conditions for the production of cytotoxic lymphocytes. Gann (Jpn J Cancer Res) 1984; 75: 1006-1016.
6. Kimura H, Yamaguchi Y. Cytotoxic activity of various LAK cells against autologous lung cancer. K-562 and Daudi cells. Jpn J Clin Oncol 1989; 19: 222-228.
7. Sekiya S, Iijima N, Oosaki T et al. A newly developed in vitro chemosensitivity test (Nuclear Damage Assay): application to ovarian cancer. Gynecol Oncol 1991; 40: 138-143.
8. Culter SJ, Ederer F. Maximum utilization of the life table methods in analyzing survival. J Chron Dis 1958; 8: 699.
9. Anderson RP, Bonchek LI, Grunkemeier SL, et al. The analysis and presentation of surgical results by actuarial methods. J Surg Res 1974; 16: 224-230.
10. Ohta M, Tsuchiya R, Shimoyama M, et al. Adjuvant chemotherapy for completely resected stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 1993; 106: 703-708.
11. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. New Eng J Med 1988; 319: 1676-1680.
12. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. New Engl J Med 1987; 316: 889-897.
13. Melief CJM. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992; 58: 143-175.
14. Kedar E, Klein E. Cancer immunotherapy; are the results discouraging? Can they be improved? Adv Cancer Res 1992; 59: 245-322.
15. Kadoyama C, Kimura H, Yamaguchi Y. Inhibition of cytotoxicity to autologous tumor cells by the regional lymph node cells of patients with primary lung cancer. Jpn J Clin Oncol 1987; 17: 29-39.
16. Naor D, Klein BY, Tarcic N, Duke-Cohen JS, editors. Immunosuppression and human malignancy. Clifton. NJ: Humana, 1989.
17. Watanabe Y, Hashizume Y, Shimizu J, et al. Functional character and augmentation of lymphocytes in regional lymph nodes of patients with lung cancer. Am Rev Respir Dis 1990; 142: 769-774.
18. Nakamura H, Ishiguro K, Mori T. Different immune functions of peripheral blood, regional lymph node, and tumor infiltrating lymphocytes in lung cancer patients. Cancer 1988; 62: 2489-2497.
19. Greenberg PD, Klarnet JP, Kern DE, et al. Therapy of disseminated tumors by adoptive transfer of specifically immune T cells. Prog Exp Tumor Res 1988; 32: 104-127.
20. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+ , 2H4+ suppressor-inducer T-cells. Cancer Res 1988; 48: 1671-1675.
21. Eastman A, Grant S, Lock R, et al. Cell death in cancer and development - AACR special conference in cancer research. Cancer Res 1994; 54: 2812-2818.
22. Hanabuchi S, Koyanagi M, Kawasaki A, et al. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci 1994; 91: 4930-4934.
23. 2+ independent T cell-mediated cytotoxicity. J Exp Med 1993; 177; 195-200.